secwatch.observer — SEC 8-K summary
======================================

Issuer:     Crinetics Pharmaceuticals, Inc. (CRNX)
CIK:        0001658247
Form:       8-K
Filed at:   2024-05-22T23:59:59+00:00
Accession:  0001193125-24-144484
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Crinetics announces early release of ENDO 2024 late-breaking abstracts for atumelnant Phase 2 CAH study
--------------------------------------------------------------------------------

- Late-breaking abstracts for atumelnant (CRN04894) Phase 2 CAH study released before embargo.
- Abstract contained summary data on 4 subjects; data from 6 subjects in cohort 1 and cohort 2 to be presented June 3, 2024.
- Full data set will be presented at ENDO 2024 poster session on June 1-2 pm ET.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658247/000119312524144484/0001193125-24-144484-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658247/000119312524144484/d815433d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-144484

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer